Can Galectin-3 Predict Postoperative Adverse Outcomes After Cardiac Transplantation? A Systematic Review

10154 

Abstract Submission 

M. Papus Keita (1)

(1) Case Western Reserve University, Shaker Heights, OH

M. Papus Keita    -  Contact Me
Case Western Reserve University

M. Papus Keita    -  Contact Me
Case Western Reserve University

Can Galectin-3 Predict Postoperative Adverse Outcomes After Cardiac Transplantation? A Systematic Review

Adham H. El-Sherbini2, Papus Keita1, MD, Yasi r Abu-Omar1, MD, PhD, Marc Pelletier, MD, Gabriel A. Rabinovich4, PhD, Mohammad El-Diasty1*, MD, PhD
1Harrington Heart and Vascular Institute, University Hospital Cleveland Medical Center, Cleveland, Ohio, USA. 2Faculty of Health Sciences, Queen's University, Kingston, ON, Canada
3Queen's University School of Medicine, Kingston, ON, Canada. 3Division of Cardiology, Department of Medicine, Queen's University, Kingston, ON, Canada. 4Laboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas and Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
--------------------------------------------------------------------------------------------------------------------
Objective: To integrate biological and clinical data, particularly related to the role of galectin-3 in cardiac fibrosis, highlighting its potential role in predicting postoperative adverse outcomes in patients undergoing heart transplantation surgery.
Methods: We performed a literature review which was conducted in accordance with the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Medline, Embase, Cochrane, and Google Scholar databases were searched using a predetermined strategy.
Results: A total of 385 citations were found, of which 26 underwent full-text review, and 6 citations with independent samples (n=1056) met full inclusion/exclusion criteria. The reported outcomes included all-cause mortality, myocardial fibrosis, acute cellular rejection, antibody-mediated rejection, and chronic allograft vasculopathy. The relationship between pre- and post-operative galectin-3 levels was explored in three studies and demonstrated the potential utility of measuring galectin-3, both at pre-transplant and post-transplant settings, for all-cause survival prognosis and adverse outcomes.
Conclusion: Galectin-3 may have a role in predicting allograft dysfunction and mortality in patients after heart transplantation surgery; however, more robust evidence is required to justify its routine use in this group of patients.

Heart Transplant